Search for other works by this author on: ...

1Seoul National University, Seoul, Korea, Republic of.

Cancer Immunotherapies (CITs) have shown unprecedented results in improving tumor control. However, many patients are still refractory to treatment. A deeper understanding of CIT-drugs mode of action ...

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment, delivering impressive results across various cancers. However, resistance is common, and only a limited number of patients ...

The NIH recently announced a cap of 15% on indirect costs for new grants. This plan has been temporarily blocked in federal court with a hearing scheduled for February 21. If cuts are implemented, ...

A Centers for Disease Control and Prevention (CDC) meeting on vaccines originally scheduled for next week has been postponed, according to a senior official from the Department of Health and Human ...

Major Finding: Myeloid-derived suppressor cells (MDSC) crosstalk with IDH–wild-type glioblastoma and promote tumor growth. Concept: Signaling between MDSCs and tumor cells support cell survival in ...

Copyright held by the owner/author(s).

Research shows that chimeric antigen receptor (CAR) T cells can endow other immune cells with their cancer-killing abilities through trogocytosis, the exchange of cell-surface proteins with ...

A woman who received chimeric antigen receptor (CAR) T-cell therapy for neuroblastoma as a girl in 2006 is in complete remission more than 18 years later, according to a long-term follow up report ...

The HER2×HER3 bispecific antibody zenocutuzumab demonstrated efficacy in treating rare cancers driven by NRG1 fusions, leading to its accelerated approval for certain pancreatic and lung cancers.

Major Finding: A recombinant Newcastle disease virus engineered to induce hyperacute rejection inhibited tumor growth a clinical trial. Concept: NDV-GT is an engineered oncolytic virus that induces ...